Patients with psoriatic arthritis who have enthesitis are more likely to persist on treatment with tofacitinib. A study analyzed the use of after-visit instructions at rheumatology clinics. Treatment with guselkumab provided a durable therapeutic benefit to patients with psoriatic arthritis. Reproductive health outcomes appear to be greatly impacted by the presence of rheumatic diseases. Between 1990 and 2019, the global incidence of early-onset osteoarthritis doubled. The FDA has approved tocilizumab-aazg for the treatment of rheumatoid arthritis, among other diseases. A regimen of nonoperative care prior to surgery for knee osteoarthritis was associated with good adherence. A case series presented data on the efficacy of CAR T-cell treatment in patients with rheumatic autoimmune disease. It is critical for physicians to be confident and comfortable in diagnosing and managing knee osteoarthritis. Incannex announces the first dosing in a phase 2 study of a novel drug combination comprising HCQ and CBD to treat RA. Artificial intelligence can potentially detect rheumatic heart disease with the same level of accuracy as a cardiologist. Mithu Maheswaranathan, MD, spoke about challenges, treatments, and trends in rheumatology, as well as upcoming advancements. A study aimed to create a benefit-versus-harm shared decision-making tool for hydroxychloroquine for patients with SLE. Having multiple risk factors for cardiovascular disease may increase the risk of rheumatoid arthritis treatment failure. Recent safety data significantly impacted prescribing practices for advanced RA therapies among physicians treating veterans. For adults with lupus nephritis, this specific treatment combination improves total remission rate better than others. Bimekizumab demonstrated sustained efficacy for the treatment of active axial spondyloarthritis through 52 weeks. A study provided a unique characterization of a rare: large-vessel involvement from ANCA-associated vasculitis. A study sought to identify variables distinguishing inflammatory from noninflammatory arthritis in a large cohort. Abatacept improved outcomes for rheumatoid arthritis refractory to methotrexate or TNFi versus rituximab or tocilizumab.